Galanthamine derivatives, a process for their preparation and their use as medicaments
CA 2118171 C · Owner: Hoechst Marion Roussel, Inc. · Inventors: Davis, Larry; Taberna, Veronica; Kosley, Raymond W. Jr.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention relates to compounds of the formula (see formula I) wherein R1 is hydrogen (C1-C12)alkylcarbonyl, (C1-C12)alkoxycarbonyl mono(C1-C12)alkylaminocarbonyl or di(C1-C12)alkylaminocarbonyl; R2 is (C1-C18)monoalkylaminocarbonyloxy (C1-C12)dialkylaminocarbonyloxy or aryl(C1-C4)alkylaminocarbonyloxy); R3 is hydrogen halo or (C1-C4)alkyl; or a pharmaceutically acceptable addition salt thereof; which are useful for inhibiting acetylcholinesterase and alleviating various memory dysfunctions characterized by decreased cholinergic function such as Alzheimer's disease. Pharmaceutical compositions containing the compounds and methods for making and using the compounds are also encompassed …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 14, 1994 and granted December 28, 1999. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended October 14, 2014.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 14, 2016.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.